In this presentation, recorded at a satellite symposium at the ERA-EDTA 2016 Congress, Professor Philip Kalra discusses clinical advances in the management of hyperphosphatemia.
Topics covered include:
- The prevalence of vascular calcification in both non-dialysis and dialysis-dependent CKD, and the link between vascular calcification and increased mortality
- The associations between hyperphosphatemia, vascular calcification and increased mortality in CKD patients
- Randomised controlled trials for phosphate binder interventions in CKD-MBD, including RIND, DCOR and Treat-to-Goal
- Results from Phase III trials of sucroferric oxyhydroxide, as well as safety and efficacy data from long term extension studies
- Real-wold data on sucroferric oxyhydroxide which has seen almost a doubling of the number of patients achieving their phosphate targets following a switch from other phosphate binders